Hyposialylated recombinant human erythropoietin for the treatment of nervous system disorders

The present invention relates to the fields of Biotechnology and Medicine and describes a pharmaceutical composition of recombinant human erythropoietin which is characterized by having a microheterogeneity of fucosylated N-glycans formed by bi, tri and tetra-antennary structures with mono and bi-si...

Full description

Saved in:
Bibliographic Details
Main Authors RODRIGUEZ OBAYA, TERESITA DE JESUS, GARCIA ARTALEJO, JUDEY AYMED, AMARO GONZALEZ, DANIEL ENRIQUE, HERNANDEZ DE LA ROSA, LOURDES, SARMIENTO CONDE, YANARA, DIAZ GOIRE, DAYLI, SOSA TESTE, ILIANA MARIA
Format Patent
LanguageChinese
English
Published 16.04.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the fields of Biotechnology and Medicine and describes a pharmaceutical composition of recombinant human erythropoietin which is characterized by having a microheterogeneity of fucosylated N-glycans formed by bi, tri and tetra-antennary structures with mono and bi-sialylated sialic acid residues that represent 40-60% of the total glycans, trisialylated ones that represent 40-43% of the total glycans and tetrasialylated ones that represent 10-13% of the total glycans. This glycosylation pattern confers properties to said composition that allow for its use in disorders of the nervous system. The method of obtaining the pharmaceutical composition described herein is also described.
Bibliography:Application Number: TW20209129058